CAS
ATYR

CTC Alternative Strategies’s aTyr Pharma ATYR Stock Holding History

CTC Alternative Strategies’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,600
Closed -$34.3K – 286
2024
Q1 		$34.3K Buy
+17,600
New +$30.7K 0.02% 126

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CTC Alternative Strategies's ATYR Position: Q2 2024 in Review

CTC Alternative Strategies sold out of aTyr Pharma (ATYR) in Q2 2024, closing a stake of 17,600 shares — an estimated $34.3K sold.

CTC Alternative Strategies first reported a position in ATYR in Q1 2024 and held it in 1 quarter. The position peaked at $34.3K in Q1 2024. 47 funds tracked by Wall St. Rank hold ATYR as of Q2 2024.

  • CTC Alternative Strategies reported no remaining aTyr Pharma position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 17,600 aTyr Pharma shares in Q2 2024, an estimated $34.3K.
  • CTC Alternative Strategies first reported a position in aTyr Pharma in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's aTyr Pharma position peaked at $34.3K in Q1 2024.
  • 47 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.